search
Back to results

Treatment of Strongyloides Infection (TSSI)

Primary Purpose

Strongyloides Stercoralis Infection, Strongyloidiasis

Status
Unknown status
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Ivermectin
Sponsored by
Albert Einstein College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Strongyloides Stercoralis Infection focused on measuring Ivermectin, S. stercoralis, parasite, helminth, Filariform, larvae, Baermann technique

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At least 18 years of age
  • Positive for Strongyloides serology infection (as determined by ELISA)

Exclusion Criteria:

  • Severe intestinal Strongyloides infection
  • Disseminated Strongyloidiasis infection
  • Pregnant and breastfeeding women
  • HTLV-1 co-infection
  • Patients with indeterminate results on Strongyloides serology
  • Patients who are immunosuppressed
  • Unable to read and understand consent form

Sites / Locations

  • Jacobi Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Ivermectin on Days 1 and 2

Ivermectin on Days 1 and 14

Arm Description

Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.

Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.

Outcomes

Primary Outcome Measures

Level of Strongyloides serology as measured by ELISA at 3-4 months post-treatment
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).
Level of Strongyloides serology as measured by ELISA at 6-8 months post-treatment
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).
Level of Strongyloides serology as measured by ELISA at 9-12 months post-treatment
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).

Secondary Outcome Measures

Full Information

First Posted
July 23, 2018
Last Updated
October 20, 2020
Sponsor
Albert Einstein College of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03605758
Brief Title
Treatment of Strongyloides Infection
Acronym
TSSI
Official Title
A Comparative Study of Two Regimens of Ivermectin for the Treatment of Strongyloides Stercoralis Infection
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 2012 (Actual)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albert Einstein College of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes

5. Study Description

Brief Summary
The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.
Detailed Description
Patients will be randomly assigned to receive 2 single doses of ivermectin at 200 µg/kg 2 weeks apart versus ivermectin at 200 µg/kg for 2 consecutive days. Patients will be randomized 50-50 to the study groups using the date of birth and a random number table. All patients will be interviewed to obtain the medical history during the initial evaluation. Patients will be asked about demographic data on a questionnaire written in English and Spanish. Physical exams, baseline blood cell counts, serum chemistries, HTLV-1(human T-cell lymphotrophic virus) serology, an IgE (immunoglobulin E), a stool sample for O &P, and a pregnancy test will be performed as routine care all patients currently receive in our clinic.Procedures: Strongyloides serology will be performed in the parasitology laboratory of Jacobi Hospital with an in-house ELISA that uses a 31-kDA(kilodalton) recombinant protein antigen (termed NIE) derived from L3 stage of S. stercoralis and purified from E. coli BL21 containing pET30b plasmid. Once the in-house serology is performed serum will be banked, so it can be available to run in paired with samples taken during follow up visits. Blood samples will be also collected and sent to the Laboratory of Parasitic Diseases (LPD) at the NIAID- National Institutes of Health (NIH) to perform other serological techniques including the Luciferase Immunoprecipitation Systems Assay (LIPS) based on NIE and the recombinant antigen S. stercoralis immunoreactive antigen (SsIR). In addition, stools will be collected from all patients and will be fixated in SAF(sodium acetate, acetic acid and formalin), to check for Strongyloides stercoralis larvae. If possible, fresh stool will be obtained to check for larvae using the Baermann technique and an aliquot will be frozen and sent to the NIH for DNA extraction and PCR(polymerase chain reaction as).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Strongyloides Stercoralis Infection, Strongyloidiasis
Keywords
Ivermectin, S. stercoralis, parasite, helminth, Filariform, larvae, Baermann technique

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ivermectin on Days 1 and 2
Arm Type
Active Comparator
Arm Description
Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
Arm Title
Ivermectin on Days 1 and 14
Arm Type
Active Comparator
Arm Description
Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
Intervention Type
Drug
Intervention Name(s)
Ivermectin
Other Intervention Name(s)
Stromectol
Intervention Description
Ivermectin is an anti-parasitic
Primary Outcome Measure Information:
Title
Level of Strongyloides serology as measured by ELISA at 3-4 months post-treatment
Description
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).
Time Frame
3-4 months post treatment
Title
Level of Strongyloides serology as measured by ELISA at 6-8 months post-treatment
Description
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).
Time Frame
6-8 months post treatment
Title
Level of Strongyloides serology as measured by ELISA at 9-12 months post-treatment
Description
The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. >0.3 OD (optical density) means positive for infection while <0.29 OD means negative (no infection).
Time Frame
9-12 months post treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age Positive for Strongyloides serology infection (as determined by ELISA) Exclusion Criteria: Severe intestinal Strongyloides infection Disseminated Strongyloidiasis infection Pregnant and breastfeeding women HTLV-1 co-infection Patients with indeterminate results on Strongyloides serology Patients who are immunosuppressed Unable to read and understand consent form
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christina M Coyle, MD
Phone
718-918-4455
Email
christina.coyle@einstein.yu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Herbert B Tanowitz, MD
Phone
718-430-3342
Email
herbert.tanowitz@einstein.yu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christina M Coyle, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jacobi Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Walter Vazquez, MS
Phone
718-918-7070
Email
walter.vazquez@nychhc.org

12. IPD Sharing Statement

Learn more about this trial

Treatment of Strongyloides Infection

We'll reach out to this number within 24 hrs